Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Sandoz, the generic drug arm of Novartis, has acquired rights to Pfizer’s biosimilar version of infliximab in 28 European countries. In 2015, Remicade, the brand-name version of the biologic, racked up $6.6 billion in sales for Johnson & Johnson. Infliximab is a TNF-α inhibitor used to treat autoimmune diseases such as rheumatoid arthritis and psoriasis. Sandoz must still complete Phase III clinical development and file for European regulatory approval of the biosimilar. Pfizer had to divest the program to win regulatory approval for its acquisition of Hospira.
This article has been sent to the following recipient: